Key points are not available for this paper at this time.
BACKGROUND: Ga radiolabeled to a variety of radiotracers that evaluate perfusion and organ function, and target specific biomarkers found on tumor lesions such as prostate-specific membrane antigen, somatostatin, fibroblast activation protein, bombesin, and melanocortin. MAIN BODY: Ga radiopharmaceutical production. CONCLUSION: Ga radiopharmaceuticals is presented to highlight potential challenges and opportunities facing the community.
Nelson et al. (2022) studied this question.